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ABSTRACT  
We have recently identified various small molecules endowed with good anti-influenza activity 
thanks to their ability  to disrupt the polymerase PA-PB1 subunits heterodimerization.  
In this paper, the optimization of the cycloheptathiophene-3-carboxamide scaffold was attempted, 
leading to the identification of new and more potent PA-PB1 inhibitors. The presence of 2-
hydroxybenzamido moiety at the C-2 position of the central core was particularly effective, giving 
compounds that inhibited viral growth in the low micromolar range coupled with SI values up to 
>1388. Computational studies suggested that the hydroxyl group induces a significant change of the 
binding mode of the compounds with respect to previously reported cycloheptathiophene-3-
carboxamide analogues, justifying their higher potency as PA/PB1 interaction inhibitors. 
 
 
Keywords: PA-PB1 interaction, influenza virus polymerase, protein-protein interaction inhibitors, 
influenza virus inhibitors.  
 
1. INTRODUCTION 
Influenza virus (flu) still causes high morbidity and mortality in humans because of seasonal 
epidemics and global pandemics. The high mutation rate together with the genomic reassortment 
among different viral strains lead flu to elude vaccine-induced immunity and/or to develop 
resistance to the current antiviral drugs, which are limited to neuraminidase and M2 ion channel 
inhibitors. Therefore, the development of anti-flu therapeutics exploiting new targets and/or 
innovative strategies is highly desirable. To this end, the inhibition of one or more components of 
the viral RNA-dependent RNA polymerase (RdRp) could have a bright future [1,2]. Indeed, RdRp 
is essential for virus transcription, replication, and evolution, its structure is highly conserved 
among the different flu A, B, and C strains, and it does not possess homologues in mammalian cells 
[3-6]. RdRp is a heterotrimeric complex composed of polymerase acidic protein (PA), polymerase 
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basic protein 1 (PB1), and polymerase basic protein 2 (PB2) subunits that work together in a tightly 
associated and coupled fashion [7]. Targeting the RdRp complex has been already proven to be a 
successful approach with the PB1 inhibitor favipiravir (T-705, Avigan®) [8,9], which has been 
approved in Japan to treat pandemic flu, and the PB2 inhibitor VX-787, which is currently in phase 
II clinical development [10]. 
An alternative and appealing strategy to inhibit the RdRp functions is to interfere with its correct 
assembly through protein-protein interaction (PPI) inhibitors that may have the advantage to be less 
prone to drug resistance emergence [11-14].  
During the last four years, several remarkable efforts were focused on the identification of small 
molecules as PA-PB1 subunits interaction inhibitors [14], with our groups that gave the major 
contribution [15-21]. Indeed, starting from a structure-based virtual screening on three million 
compounds using the crystallographic structure of the C-terminal domain of PA bound to a PB1-
derived peptide reported by He et al. (PDB ID 3CM8) [22], a first series of hit compounds was 
identified [15]. Structural optimization studies were successively conducted leading to the 
identification of very promising compounds that, acting through low micromolar PA-PB1 complex 
inhibition, displayed good anti-flu activity against several clinical isolates of fluA, including an 
oseltamivir-resistant strain, and of fluB [18-20]. In particular, the structural evolution of derivative 
1 (Fig. 1) allowed to improve both the antiviral and the PPI inhibitory activity, as in the p-chloro 
derivative 2 [18] (Fig. 1), together with the delineation of useful structure-activity relationship 
(SAR) insights. From these studies, it clearly emerged how minor structural modifications around 
the cycloheptathiophene-3-carboxamide (cHTC) scaffold strongly influence both the ability to 
interfere with the PA-PB1 subunits interaction and the anti-flu activity. Thus, a further optimization 
of this scaffold has been attempted in the present study, by synthesizing a new series of derivatives 
that were tested for their PPI inhibitory activity and anti-flu properties. Moreover, computational 
studies were conducted to rationalize their binding mode within the PA cavity.  
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Fig. 1. Structures of cHTC derivatives 1 and 2.  
 
2. DESIGN OF cHTC ANALOGUES 
In the first optimization study of hit compound 1, the attention was mainly focused on the C-2 
position of the cHTC scaffold: different substituents replaced the o-fluorine atom, one or two 
methylene units were inserted between the C-2 phenyl ring and the core, and the phenyl ring was 
replaced by bulky aromatic rings or a cyclohexyl moiety. Fewer modifications involved the 
cycloheptane ring, whose size was reduced to cyclohexane or cyclopentane, and the C-3 pyridinyl 
carboxamide moiety, which was replaced by smaller groups such as primary amide, ethyl 
carboxylate, and carboxylic acid [18]. From this first set of compounds, clear SAR information 
emerged: the cycloheptane cannot be replaced by smaller rings and aromatic moieties both at C-2 
and at C-3 position are required to impart potent activity.  
By analyzing the predicted binding modes of the best PA-PB1 inhibitors reported so far in the PA 
cavity from X-ray crystal structure PDB ID 3CM8 [22], it emerged that two hydrophobic 
interactions, one of which essential for the interaction with W706, seem sufficient to impart 
inhibitory activity against PA-PB1 interaction [14]. When additional hydrophobic interactions do 
not occur, favorable stabilization of the PA-small molecule interaction seems to take place with the 
formation of one (with Q408) or more favorable H-bonds.  
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By aligning some PA-PB1 inhibitors, we proposed a first pharmacophore model entailing two 
hydrophobic moieties separated by a “polar belt” with two H-bond acceptor points and two H-bond 
donor points [19]. More recently, we generated a new pharmacophore model by using all the best 
PA-PB1 inhibitors reported to date [14]. It preserves the two hydrophobic moieties, of which one 
involved in the interaction with W706. On the contrary, the two H-bond donor points do not seem 
critical for intermolecular interactions and only a H-bond acceptor point is preserved. Thus, two 
hydrophobic moieties and a central H-bond acceptor point appear to be the minimum structural 
requirement for PA-PB1 inhibition. However, since eight out of the eleven best PA-PB1 inhibitors 
studied matched two H-bond interaction points, additional H-bond interactions should be exploited 
to achieve a more efficient PA-PB1 inhibition. 
Taking into account the indications coming from the previous SAR coupled with the recent 
computational suggestions, a new set of derivatives has been designed by inserting a hydroxyl 
group to the different positions of the C-2 phenyl ring (compounds 3-5, Table 1).  
Computational studies based on the Fingerprints for Ligands and Proteins (FLAP) algorithm [23] 
were performed to analyze their binding poses in the PA cavity from the structure PDB ID 3CM8 
[22]. To be consistent with our previous results [14-16,18-20], the FLAP software was used in the 
“Structure-based” mode: this approach allows to generate binding poses of a ligand in a protein 
cavity based on the similarity between their GRID fields [24]. Thus, although this approach is not a 
standard energy-based docking method, it proved to be successful in identifying or optimizing PA-
PB1 inhibitors [15,18-20]. Similarity scores were used to rank the most reliable poses for 
compounds 3-5 (Fig. 2B-D); the FLAP binding pose previously obtained for hit compound 1 [18] 
was also reported as a reference in Fig. 2A. Compound 1 interacted with the first (defined by W706 
and F411) and the second (defined by P710 and L666) hydrophobic pockets and with the additional 
central hydrophobic region (mainly generated by the aliphatic chain of E623 and the protein 
backbone). The similarity score for the proposed binding pose of 1 was 0.53. According to our 
model, the insertion of the hydroxyl group induced a significant change of the binding mode. 
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Indeed, the hydrophobic interaction with W706, already reported as a key residue for PA-PB1 
inhibition [14], still occurred for all compounds 1 and 3-5, even though the orientation of the 
cycloheptathiophene core in compounds 3-5 resulted to be inverted with respect to 1. As a 
consequence, the hydroxyl-substituted phenyl ring pointed towards a region of the PA cavity 
defined by F411, C415, and I621. Hydrophobic and H-bond interactions contributed to obtain a 
more favorable binding mode for compounds 3-5. Based on the FLAP similarity scoring, which 
takes into account a global estimation of hydrophobic, hydrophilic, H-bond donor and H-bond 
acceptor interactions, compounds 3-5 are almost equivalent (0.65, 0.63, and 065, respectively), with 
higher values with respect to compound 1 (0.53). Thus, the similarity scores are in agreement with 
the ELISA PA-PB1 interaction assay data, shown in Table 1. A deeper visual inspection of the 
binding poses in Figure 2 was performed.  The o-hydroxyl derivative 3 displayed the most efficient 
hydrophobic interactions between the cycloheptathiophene moiety with W706 and between the 
hydroxyphenyl group with the hydrophobic region defined by F411, C415, and I621 (Fig. 2B). The 
latter hydrophobic region was recently described as another key area of PA for the interaction with 
potent inhibitors [25]. In addition, compound 3 resulted able to form a H-bond between I621 and its 
hydroxyl group, and a second one between the C-3 carbonyl group and Q408. On the contrary, the 
FLAP binding poses for the meta and para isomers 4 and 5 resulted shifted towards C415, 
weakening the hydrophobic interaction with W706 (Fig. 2C-D). This shift could allow 5 to form a 
new H-bond interaction between the p-hydroxyl group and the carbonyl group of C415, while the 
m-hydroxyl group was not involved in any specific interaction. Additional H-bonds with I621 and 
Q408 were still possible for both compounds 4 and 5.  
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Fig. 2. FLAP binding poses for compounds 1 (A), 3 (B), 4 (C), and 5 (D). Some of the PA key 
residues located in the cavity are highlighted in stick-mode.  
 
In agreement with the computational study, the biological evaluation of the three isomers (3, 4, and 
5) showed that the hydroxyl group resulted useful to impart PA-PB1 interaction inhibitory activity 
especially when placed at ortho position (IC50 = 15 μM), and also allowed to achieve a really potent 
anti-flu activity (EC50 = 2.6 μM).  
Given the potent antiviral profile of compound 3, the o-hydroxyphenyl moiety was maintained at 
the C-2 position while the C-3 position was thoroughly explored in a successive set of derivatives 
(compounds 6-16, Table 1). In particular, the 2-pyridinyl ring was replaced by a phenyl (6), p-
chlorophenyl (7), p-fluorophenyl (8), and also by a thiazole (9) ring. A methylene unit was inserted 
between the aromatic ring and amide moiety at the C-3 position, as in compounds 10 and 11. 
Aliphatic alkyl moieties, i.e. isopropyl, tert-butyl, cyclohexyl, piperazine, and 2-pyridilpiperazine 
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(12-16), were also used as C-3 substituents. Methoxy intermediates 17 [26], 18, and 19 (Table 1) 
were also assayed to enrich the SAR. The replacement of the hydroxyl group at the C-2 phenyl ring 
was also investigated with the o-amino and p-amino derivatives 20 [26] and 21 [26] (Table 1). 
Finally, the C-2 and C-3 aromatic groups were interchanged synthesizing compounds 22 and 23 
(Table 1).    
 
3. CHEMISTRY 
The synthesis of the target compounds 3-9, 14, 18, 19, 22, and 23 was accomplished by applying 
the two-steps Gewald synthesis, as outlined in Scheme 1. Thus, the 2-cyano-N-(substituted)-
acetamides 25 [27], 26 [28], 27, 28 [27], and 29-31, prepared by reacting 3-(3,5-dimethyl-1H-
pyrazol-1-yl)-3-oxopropanenitrile 24 [27] with the appropriate amines in toluene, were used in a 
first Knoevenagel condensation with cycloheptanone. The successive cyclization step performed in 
the presence of sulfur and N,N-diethylamine in EtOH gave synthones 32 [18], 33 [29], and 34-38. 
The reaction of synthones 32-38 with the appropriate acyl chlorides in dry pyridine led to the 
methoxyl derivatives 17 [26], 18, 19, and 39-45. The successive O-demethylation performed with 
BBr3 in dry CH2Cl2 provided the hydroxyl target compounds 3-9, 14, 22, and 23. 
An alternative strategy was used for the synthesis of the target compounds 10-13, 15 and 16 
(Scheme 2), all characterized by the o-hydroxyl phenyl ring at C-2 position, entailing the 
preparation of the key intermediate 48 suitable to be widely functionalized at the C-3 position. 
Thus, synthone 48 was prepared by reacting ethyl 2-amino-5,6,7,8-tetrahydro-4H-
cyclohepta[b]thiophene-3-carboxylate 46 [30] with the 2-methoxybenzoyl chloride in dry pyridine, 
to obtain derivative 47 that was then hydrolyzed under basic conditions. Coupling reaction of 3-
carboxylic acid 48 with the appropriate alkyl amines in presence of benzotriazol-1-
yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) and collidine in dry CH2Cl2 
gave the desired 2-methoxybenzamido derivatives 49-54. Of note, the coupling reaction carried out 
in the same conditions but using anilines for the synthesis of the target compounds shown in 
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Scheme 1, did not furnish the desired compounds but gave only the cyclized 
cyclohepta[4,5]thieno[2,3-d][1,3]oxazin-4-one derivatives. The o-hydroxy target derivatives 10-13, 
15, and 16 were then obtained by O-demethylation of methoxyl intermediates 49-54 in the presence 
of BBr3 in dry CH2Cl2.  
 
 
Scheme 1. Synthesis of compounds 3-9, 14, 18, 19, 22, and 23. Reagents and conditions: (i) 
amines, toluene, reflux; (ii) cycloheptanone, ammonium acetate, glacial acetic acid, benzene, reflux; 
(iii) sulfur, N,N-diethylamine, EtOH, 40−50 °C; (iv) acyl chlorides, pyridine, rt; (v) BBr3, dry 
CH2Cl2, rt.  
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Scheme 2. Synthesis of compounds 10-13, 15, and 16. Reagents and conditions: (i) 2-
methoxybenzoyl chloride, pyridine, rt; (ii) LiOH, H2O/THF, 50 °C; (iii) amines, BOP, collidine, dry 
CH2Cl2, rt; (iv) BBr3, dry CH2Cl2, rt. 
 
4. RESULTS AND DISCUSSION 
The whole set of derivatives were first evaluated for the ability to inhibit the physical interaction 
between fluA PA and PB1 subunits by ELISA including the PB1(1–15)–Tat peptide [31] as a positive 
control of inhibition. In parallel, for all the synthesized compounds the antiviral activity was tested 
by plaque reduction assays (PRA) in Mardin-Darby canine kidney (MDCK) cells infected with a 
reference fluA virus, the A/PR/8/34 strain. Ribavirin (RBV), a known broad-spectrum inhibitor of 
RNA viruses polymerase [32], was included as a positive control of inhibition. To exclude that the 
observed antiviral activities could be due to toxic effects on the target cells, all the synthesized 
compounds were also tested by MTT assays in MDCK cells. The antiviral activity and toxicity data 
for the tested compounds, as well as their ability to disrupt the PA-PB1 interaction in ELISA, are 
reported in Table 1. 
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Table 1.  Structure and Biological Activity of the cHTCs Synthesized in This Study. 
 
Compd R1 R2 
ELISA 
PA-PB1 
Interaction 
Assay 
IC50, µMa 
PRA 
in MDCK cells 
EC50, µMb 
Cytotoxicity 
(MTT Assay) in  
MDCK cells 
CC50, µMc 
1 
 
 
145 ± 12 90 ± 13 >250 
2 
 
“ 32 ± 9 18 ± 2 >250 
3 
 
“ 15 ± 2 2.6 ± 0.5 >250 
4 
 
“ 23 ± 6 22 ± 9 248 ± 1 
5 
 
“ 26 ± 4 19 ± 2 >250 
6 
 
 
58 ± 16 30 ± 1 >250 
7 “ 
 
18 ± 1 1.2 ± 0.3 >250 
8 “ 
 
20 ± 5 1.2 ± 0.4 >250 
9 “ 
 
69 ± 15 0.18 ± 0.07 >250 
10 “ 
 
33 ± 6 >100 >250 
11 “ 
 
191 ± 21 >100 172 ± 18 
12 “ 
 
>200 >100 >250 
12 
 
13 “ 
 
156 ± 8 >100 >250 
14 “ 
 
114 ± 21 >100 172 ± 39 
15 “ 
 
>200 94 ± 6 >250 
16 “ 
 
197 ± 15 >100 145 ± 7 
17d 
 
 
22 ± 2 86 ± 8 147 ± 39 
18 
 
 
45 ± 14 24 ± 6 >250 
19 
 
 
78 ± 11 82 ± 3 >250 
20d 
 
 
>200 101 ± 6 >250 
21d 
 
“ 65 ± 20 0.26 ± 0.13 >250 
22 
 
 
26 ± 6 1.8 ± 1.0 28 ± 8 
23 
 
“ 118 ± 21 8.2 ± 1.1 >250 
RBV    10 ± 2 >250 
Tat-PB11-15 
peptide   35 ± 4 41 ± 5 >100 
a Activity of the compounds in ELISA PA-PB1 interaction assays. The IC50 value represents the compound 
concentration that reduces by 50% the interaction between PA and PB1. b Activity of the compounds in plaque 
reduction assays with the flu A A/PR/8/34 strain. The EC50 value represents the compound concentration that inhibits 
50% of plaque formation. c Activity of the compounds in MTT assays. The CC50 value represents the compound 
concentration that causes a decrease of cell viability of 50%. All the reported values represent the means ± SD of data 
derived from at least three independent experiments in duplicate. d Reported in reference [26]. 
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With the aim to exploit polar groups able to establish important H-bonds, the hydroxyl derivatives 
3-5 were initially prepared. The ortho hydroxyl derivative 3 was the most active, being able to 
efficiently interfere with PA-PB1 interaction (IC50 = 15 µM) and exhibiting potent antiviral activity 
(EC50 = 2.6 µM) without showing cytotoxicity (CC50 > 250 μM), resulting in a selectivity index (SI) 
> 96. The shifting of the hydroxyl group to meta and para positions (compounds 4 and 5, 
respectively) decreased both the PA-PB1 interaction inhibitory activity and mainly the antiviral 
effect. Within the C-2 o-hydroxyl phenyl derivatives variously functionalized at C-3 position, para 
halogenated derivatives 7 and 8 showed a good anti-flu activity in the cellular context, even better 
than compound 3, with EC50 values of 1.2 µM; in addition, the absence of cytotoxicity up to 250 
µM led to SIs > 200. Also the C-3 thiazole ring improved the anti-flu activity; indeed, compound 9 
emerged as the most potent of the series with an EC50 of 0.18 µM, which coupled with the lack of 
cytotoxicity up to 250 µM led to the impressive SI > 1388; however, compound 9 showed a 
decreased ability to inhibit the PPI. Conversely, compound 6, having a nude phenyl ring as C-3 
substituent, was found to be a weak inhibitor of both PA-PB1 interaction and flu growth. The 
introduction of a methylene unit as a spacer between the aromatic ring and the scaffold (compounds 
10 and 11) as well as the replacement of the aromatic ring with aliphatic substituents (compounds 
12-16) at the C-3 position were in all cases detrimental.  
The o-hydroxyl phenyl moiety still conferred anti-PA-PB1 and above all anti-flu activity when 
moved to the C-3 position and coupled with the C-2 p-chlorophenyl ring, as in compound 22, even 
though it caused cytotoxicity. The similar anti-PA-PB1 effect displayed by compound 22 and its 
analogue 2 was also confirmed by FLAP-computational studies, suggesting that the two compounds 
exhibit a similar binding pose in the PA cavity, with the p-chloro substituent likely oriented into an 
enlarged hydrophobic pocket generated by L666 and a rotated P710 (not shown). For what concerns 
the other C-3 hydroxyphenyl compound 23, although showing good ability to inhibit viral growth at 
nontoxic concentrations, only a weak anti-PA-PB1 activity was observed.  
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The ability to interfere with PA-PB1 binding and mainly the antiviral activity dramatically 
decreased when the hydroxyl group was replaced with a methoxyl group, such as in compounds 17-
19, as compared with their counterparts 3, 22, and 7, respectively. Also the replacement of the 
hydroxyl with an amino group both in ortho (compound 20) and para (compound 21) position was 
detrimental for what concerns the PA-PB1 inhibition. However, the p-amino derivative 21 exhibited 
a very potent anti-flu activity with EC50 of 0.26 µM and it was found to be not cytotoxic in MDCK 
cells (CC50 > 250), reaching an SI > 961.  
 
5. CONCLUSIONS 
The continuous need to identify innovative anti-flu compounds led us to explore the subunits 
assembly of RdRp as a possible alternative antiviral target. This approach has already proven to be 
successful with the identification of effective PA-PB1 interaction inhibitors endowed with the 
ability to inhibit flu growth. 
In this study we came back  to the cHTC scaffold, which was functionalized with a hydroxyl moiety 
with the aim of exploiting additional H-bond interactions with key residues of the PA cavity, as 
suggested by recent computational studies [14]. As a result, new very interesting compounds were 
identified. In particular, C-2 o-hydroxyphenyl derivatives 3, 7, and 8 emerged as the best in 
inhibiting PA-PB1 interaction that well translated into a potent anti-flu activity. Two additional 
compounds, C-3 thiazole derivative 9 and C-2 p-aminophenyl compound 21, although showing a 
weaker ability to inhibit PA-PB1 interaction, were endowed with a very potent anti-flu activity 
(IC50 = 0.18 and 0.26 μM), reaching SI values >1388 and >961, respectively. For these compounds, 
further studies are in progress to uncover whether an additional mechanism of action might 
contribute to their potent anti-influenza activity. 
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6. Experimental section 
6.1. Computational methods 
The binding poses in the PA cavity were generated using the FLAP software in the structure-based 
mode (Molecular Discovery Ltd., UK; www.moldiscovery.com). The procedure has been 
extensively described elsewhere [16]. As in the previous studies, the main cavity of the 
crystallographic structure of a large C-terminal fragment of PA (aa 257-716) (pdb code: 3CM8) 
[22] was used as a template. A total of 50 conformers for each ligand were generated to mimic the 
compound flexibility, and the most abundant protonation state of each molecule was used, as 
predicted by MoKa [33]. The probes used to generate the GRID Molecular Interaction Fields were 
H (shape), DRY (hydrophobic interactions), N1 (H-bond donor) and O (H-bond acceptor) 
interactions. The global similarity score (Glob-Pro) was used for ranking. 
 
6.2. Chemistry 
6.2.1. General experimental procedures 
Commercially available starting materials, reagents, and solvents were used as supplied. All 
reactions were routinely checked by TLC on silica gel 60F254 (Merck) and visualized by using UV 
or iodine. Flash column chromatography was performed on Merck silica gel 60 (mesh 230-400). 
After extraction, organic solutions were dried over anhydrous Na2SO4, filtered, and concentrated 
with a Büchi rotary evaporator at reduced pressure. Yields are of purified product and were not 
optimized. HRMS spectra were registered on Agilent Technologies 6540 UHD Accurate Mass Q-
TOF LC/MS, HPLC 1290 Infinity. Purity of the target compounds was determined by LC/MS on 
Agilent Technologies 6550 iFUNNEL Q-TOF equipped with HPLC 1290 Infinity with DAD 
detector. HPLC conditions to assess the purity of final compounds were as follows: column, 
Phenomenex AERIS Widepore C4, 4.6mm  × 100 mm (6.6 μm); flow rate, 0.85 mL/min; 
acquisition time, 10 min; DAD 190−650 nm; oven temperature, 30 °C; gradient of acetonitrile in 
water containing 0.1% of formic acid (0−100% in 10 min). Analyses indicated by the symbols of 
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the elements or functions were within ± 0.4 % of the theoretical values. 1H NMR and 13C NMR 
spectra were recorded on Bruker Avance DPX-200 and Bruker Avance DRX-400MHz using 
residual solvents such as dimethylsulfoxide (δ = 2.48) as an internal standard. Chemical shifts were 
recorded in ppm (δ) and the spectral data are consistent with the assigned structures. The spin 
multiplicities are indicated by the symbols s (singolet), d (doublet), t (triplet), q (quartet), m 
(multiplet), and bs (broad singolet).   
The synthesis of some compounds reported in this study, i.e., 17 [26], 20 [26], 21 [26], 24 [27], 28 
[27], 32 [18], 33 [29], and 46 [30], has been previously described. Derivatives 34-36, 38, and 48 are 
commercially available but their synthesis has been not published before and is herein reported. The 
synthesis of compounds 27 [28], 29 [34], 30 [35], and 31 [36] has been previously described but 
their preparation is herein reported through a  different synthetic strategy. 
6.2.2. General procedure for the preparation of 2-cyano-N-(substituted)acetamides 27 and 29-31 
(Method A). To a solution of the appropriate amine (1.0 equiv) in toluene, 24 [27] (1.0 equiv) was 
added. The mixture was refluxed for 5 min, and then stirred at room temperature to obtain a 
precipitate, which was filtered, washed with Et2O, and dried. 
6.2.3. N-(4-Chlorophenyl)-2-cyanoacetamide (27). The tile compound was prepared starting from 
p-chloroaniline through Method A, in 84% yield as white solid. 1H NMR (200 MHz, DMSO-d6):  
3.80 (s, 2H, CH2), 7.35 (d, J = 8.8 Hz, 2H, aromatic CH), 7.50 (d, J = 8.8 Hz, 2H, aromatic CH), 
10.25 (bs, 1H, NH). 
6.2.4. 2-Cyano-N-(4-fluorophenyl)acetamide (29). The tile compound was prepared starting from p-
fluoroaniline through Method A, in 87% yield as white solid. 1H NMR (200 MHz, DMSO-d6):  
3.75 (s, 2H, CH2), 7.00-7.20 (m, 2H, aromatic CH), 7.40-7.50 (m, 2H, aromatic CH), 10.50 (bs, 1H, 
NH). 
6.2.5. 2-Cyano-N-(thiazol-2-yl)acetamide (30). The tile compound was prepared starting from 2-
aminothiazole through Method A, in 87% yield as white solid. White solid. 1H NMR (200 MHz, 
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DMSO-d6,):  4.00 (s, 2H, CH2), 7.20 and 7.45 (d, J = 3.5 Hz, each 1H, aromatic CH) 12.50 (bs, 
1H, NH). 
6.2.6. 2-Cyano-N-cyclohexylacetamide (31) The tile compound was prepared starting from 
cyclohexylamine through Method A, in 72% yield as white solid. 1H NMR (200 MHz, DMSO-d6): 
 1.00-1.45 and 1.50-1.80 (m, each 5H, cyclohexyl CH2), 3.45-3.50 (m, 1H, cyclohexyl CH), 3.55 
(s, 1H, CH2), 8.05 (d, J = 7.6 Hz, 1H, NH). 
6.2.7. General procedure for the preparation of 2-amino-N-(substituted)-cycloheptathiophene-3-
carboxamide synthones 34-38 (Method B). By applying a two-steps Gewald synthesis, a mixture of 
the appropriate 2-cyano-N-(substituted)acetamide (1.0 equiv), cycloheptanone (4.0 equiv), 
ammonium acetate (1.3 equiv), and glacial acetic acid (3.5 equiv) in benzene (10 ml/mmol) was 
heated at reflux for 16 h in a Dean-Stark apparatus. After cooling, the mixture was diluted with 
CHCl3 and then washed with H2O, 10% NaCO3 solution, and finally H2O. The organic layer was 
concentrated to dryness to afford the crude Knoevenagel product, which was used directly in the 
successive step without further purification. Thus, to the crude Knoevenagel product (1.0 equiv) 
dissolved in EtOH, sulfur (4.0 equiv) and N,N-diethylamine (4.0 equiv) were added. The mixture 
was maintained at 40-50 °C for 2 h and then concentrated to dryness to yield a residue, which was 
treated with a mixture of cyclohexane/Et2O and filtered.  
6.2.8. 2-Amino-N-(4-chlorophenyl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide 
(34).The title compound was prepared starting from 27 through Method B, in 61% yield as red-
brown solid. 1H NMR (400 MHz, DMSO-d6):  1.40-1.60 (m, 4H, cycloheptane CH2), 1.65-1.80 
(m, 2H, cycloheptane CH2), 2.40-2.55 and 2.60-2.70 (m, each 2H, cycloheptane CH2), 5.80 (bs, 2H, 
NH2), 7.25 (d, J = 8.8 Hz, 2H, aromatic CH), 7.60 (d, J = 8.8 Hz, 2H, aromatic CH), 9.55 (bs, 1H, 
NH). 
6.2.9. 2-Amino-N-phenyl-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide (35). The 
title compound was prepared starting from 28 [27] through Method B, in 64% yield as red-brown 
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solid. 1H NMR (200 MHz, CDCl3):  1.40-1.70 (m, 4H, cycloheptane CH2), 1.75-1.85 (m, 2H, 
cycloheptane CH2), 2.50-2.60 and 2.75-2.85 (m, each 2H, cycloheptane CH2), 5.05 (s, 2H, NH2), 
7.05 (t, J = 7.2 Hz, 1H, aromatic CH), 7.20-7.35 (m, 2H, aromatic CH), 7.45 (d, J = 7.9 Hz, 2H, 
aromatic CH), 9.50 (s, 1H, NH). 
6.2.10. 2-Amino-N-(4-fluorophenyl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide 
(36). The title compound was prepared starting from 29 through Method B, in 41% yield as red-
brown solid. 1H NMR (400 MHz, DMSO-d6):  1.40-1.60 (m, 4H, cycloheptane CH2), 1.60-1.90 
(m, 2H, cycloheptane CH2), 2.50-2.70 (m, 4H, cycloheptane CH2), 5.75 (bs, 2H, NH2), 6.90-7.10 
(m, 2H, aromatic CH), 7.70-7.85 (m, 2H, aromatic CH), 9.50 (s, 1H, NH). 
6.2.11. 2-Amino-N-(thiazol-2-yl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide 
(37). The title compound was prepared starting from 30 through Method B, in 40% yield as yellow 
solid. 1H NMR (200 MHz, CDCl3):  1.50-1.70 (m, 4H, cycloheptane CH2), 1.75-1.85 (m, 2H, 
cycloheptane CH2), 2.50-2.60 and 2.75-2.85 (m, each 2H, cycloheptane CH2), 5.15 (s, 2H, NH2), 
6.90 and 7.30 (d, J = 3.6 Hz, each 1H, aromatic CH), 10.00 (s, 1H, NH). 
6.2.12. 2-Amino-N-cyclohexyl-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide (38). 
The title compound was prepared starting from 31 through Method B, in 55% yield as light-brown 
solid. 1H NMR (200 MHz, DMSO-d6):  1.00-1.25 and 1.40-1.55 (m, each 5H, cyclohexyl CH2), 
1.60-1.75 (m, 8H, cycloheptane CH2), 2.50-2.60 (m, 2H, cycloheptane CH2), 3.50-3.60 (m, 1H, 
cyclohexyl CH), 5.50 (bs, 2H, NH2), 7.20 (d, J = 7.6 Hz, 1H, NH). 
6.2.13. General procedure for C-2 amidation for derivatives 18, 19, and 39-45 (Method C). A 
solution of the appropriate synthones (1.0 equiv) in dry pyridine was added of the suitable benzoyl 
chloride (2.0 equiv). The reaction mixture was maintained at room temperature until no starting 
material was detected by TLC. After cooling, the reaction mixture was poured into ice/water, 
obtaining a precipitate which was filtered and purified as described below.  
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6.2.14. 2-(4-Chlorobenzamido)-N-(2-methoxyphenyl)-5,6,7,8-tetrahydro-4H-
cyclohepta[b]thiophene-3-carboxamide (18). The title compound was prepared starting from 33 
[29] through Method C and purified by crystallization by EtOH, in 29% yield as light-yellow solid. 
1H NMR (200 MHz, CDCl3):  1.50-1.80 (m, 4H, cycloheptane CH2), 1.80-2.00 (m, 2H, 
cycloheptane CH2), 2.70-2.80 and 2.90-3.00 (m, each 2H, cycloheptane CH2), 3.90 (s, 3H, OCH3), 
6.80 (dd, J = 1.8 and 7.3 Hz, 1H, aromatic CH), 7.05 (dt, J = 2.0 and 7.5 Hz, 2H, aromatic CH), 
7.45 (d, J = 8.7 Hz, 2H, aromatic CH), 7.90 (d, J = 8.7 Hz, 2H, aromatic CH), 8.10 (s, 1H, NH), 
8.45 (dd, J = 1.8 and 7.4 Hz, 1H, aromatic CH), 12.00 (s, 1H, NH). HRMS: m/z calcd for 
C24H23ClN2O3S 455.1197 (M+H)+, found 455.1198. 
6.2.15. N-(4-Chlorophenyl)-2-(2-methoxybenzamido)-5,6,7,8-tetrahydro-4H-
cyclohepta[b]thiophene-3-carboxamide (19). The title compound was prepared starting from 34 
through Method C and purified by flash chromatography eluting with cyclohexane:EtOAc 6:4, in 
21% yield as red-brown solid. 1H NMR (200 MHz, CDCl3):  1.55-1.65 (m, 4H, cycloheptane 
CH2), 1.65-1.75 (m, 2H, cycloheptane CH2), 2.55-2.65 and 2.65-2.80 (m, each 2H, cycloheptane 
CH2), 4.00 (s, 3H, OCH3), 6.95 (d, J = 8.3 Hz, 1H, aromatic CH), 7.10 (t, J = 7.2 Hz, 1H, aromatic 
CH), 7.35 (d, J = 8.8 Hz, 2H, aromatic CH), 7.40-7.50 (m, 2H, aromatic CH and NH), 7.60 (d, J = 
8.7 Hz, 2H, aromatic CH), 8.25 (dd, J = 8.07 and 1.9 Hz, 1H, aromatic CH), 12.10 (s, 1H, NH). 
HRMS: m/z calcd for C24H23ClN2O3S 455.1197 (M+H)+, found 455.1196. 
6.2.16. 2-(3-Methoxybenzamido)-N-(pyridin-2-yl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (39). The title compound was prepared starting from 32 [18] through Method C and 
purified by flash chromatography eluting with cyclohexane:EtOAc 7:3, in 41% yield as red-brown 
solid. 1H NMR (400 MHz, DMSO-d6):  1.50-1.60 (m, 4H, cycloheptane CH2), 1.80-1.90 (m, 2H, 
cycloheptane CH2), 2.70-2.85 (m, 4H, cycloheptane CH2), 3.75 (s, 3H, OCH3), 7.05-7.15 (m, 2H, 
aromatic CH and pyridine CH), 7.35-7.45 (m, 3H, aromatic CH), 7.70-7.80 (m, 1H, pyridine CH), 
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8.10 (d, J = 8.2 Hz, 1H, pyridine CH), 8.25-8.30 (d, 1H, pyridine CH), 10.30 and 10.90 (s, each 1H, 
NH). 
6.2.17. 2-(4-Methoxybenzamido)-N-(pyridin-2-yl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (40). The title compound was prepared starting from 32 [18] through Method C and 
purified by treatment with Et2O, in 34% yield, as red-brown solid. 1H NMR (200 MHz, DMSO-d6): 
 1.40-1.60 (m, 4H, cycloheptane CH2), 1.65-1.80 (m, 2H, cycloheptane CH2), 2.60-2.80 (m, 4H, 
cycloheptane CH2), 3.80 (s, 3H, OCH3), 6.95 (d, J = 8.7 Hz, 2H, aromatic CH), 7.05-7.15 (m, 1H, 
pyridine CH), 7.70-7.85 (m, 3H, aromatic CH and pyridine CH), 8.15 (d, J = 8.3 Hz, 1H, pyridine 
CH), 8.25-8.35 (m, 1H, pyridine CH), 10.30 and 10.90 (s, each 1H, NH). 
6.2.18. N-(3-((2-Methoxyphenyl)carbamoyl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-2-
yl)picolinamide (41). The title compound was prepared starting from 33 [29] through Method C and 
purified by flash chromatography eluting with CHCl3:MeOH 98:2, in 34% yield as light-yellow 
solid. 1H NMR (400 MHz, DMSO-d6):  1.55-1.70 (m, 4H, cycloheptane CH2), 1.75-1.85 (m, 2H, 
cycloheptane CH2), 2.70-2.80 and 2.80-2.90 (m, each 2H, cycloheptane CH2), 3.80 (s, 3H, OCH3), 
6.95 (t, J = 7.3 Hz, 1H, aromatic CH), 7.05 (d, J = 7.4 Hz, 1H, aromatic CH), 7.10 (t, J = 7.1 Hz, 
1H, aromatic CH), 7.55-7.65 (m, 1H, pyridine CH), 7.90 (d, J = 7.7 Hz, 1H, pyridine CH), 8.00-
8.20 (m, 2H, pyridine and aromatic CH), 8.70 (d, J = 4.7 Hz, 1H, pyridine CH), 8.80 (s, 1H, NH), 
12.20 (s, 1H, NH). 
6.2.19. 2-(2-Methoxybenzamido)-N-phenyl-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (42). The title compound was prepared starting from 35 through Method C and 
purified by flash chromatography eluting with cyclohexane:EtOAc 7:3, in 32% yield as white solid. 
1H NMR (200 MHz, DMSO-d6):  1.45-1.70 (m, 4H, cycloheptane CH2), 1.75-1.85 (m, 2H, 
cycloheptane CH2), 2.65-2.80 (m, 4H, cycloheptane CH2), 3.80 (s, 3H, OCH3), 7.00-7.20 (m, 3H, 
aromatic CH), 7.30 (t, J = 7.6 Hz, 2H, aromatic CH), 7.50 (t, J = 7.1 Hz, 1H, aromatic CH), 7.70 (d, 
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J = 7.5 Hz, 2H, aromatic CH), 8.00 (d, J = 6.7 Hz, 1H, aromatic CH), 10.10 and 11.60 (s, each 1H, 
NH). 
6.2.20. N-(4-Fluorophenyl)-2-(2-methoxybenzamido)-5,6,7,8-tetrahydro-4H-
cyclohepta[b]thiophene-3-carboxamide (43). The title compound was prepared starting from 36 
through Method C and purified by treatment with Et2O, in 74% yield as light-brown solid. 1H NMR 
(200 MHz, DMSO-d6):  1.60-2.00 (m, 6H, cycloheptane CH2), 2.60-2.75 (m, 4H, cycloheptane 
CH2), 3.75 (s, 3H, OCH3), 7.00-7.25 (m, 4H, aromatic CH), 7.50-7.60 (m, 1H, aromatic CH), 7.70-
7.80 (m, 2H, aromatic CH), 8.00 (d, J = 7.5 Hz, 1H, aromatic CH), 10.20 and 11.75 (s, each 1H, 
NH).    
6.2.21. 2-(2-Methoxybenzamido)-N-(thiazol-2-yl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (44). The title compound was prepared starting from 37 through Method C and 
purified by flash chromatography eluting with cyclohexane:EtOAc 6:4, in 32% yield as yellow-
orange solid. 1H NMR (400 MHz, CDCl3):  1.55-1.65 (m, 4H, cycloheptane CH2), 1.75-1.85 (m, 
2H, cycloheptane CH2), 2.70-2.80 and 2.85-2.90 (m, each 2H, cycloheptane CH2), 4.15 (s, 3H, 
OCH3), 6.90 (d, J = 3.5 Hz, 1H, aromatic CH), 6.95-7.00 (m, 2H, aromatic CH), 7.15 (t, J = 7.5 Hz, 
1H, aromatic CH), 7.45 (dt, J = 1.7 and 8.6 Hz, 1H, aromatic CH), 8.25 (dd, J = 1.7 and 7.8 Hz, 1H, 
aromatic CH), 11.40 and 12.40 (s, each 1H, NH). 
6.2.22. N-Cyclohexyl-2-(2-methoxybenzamido)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (45). The title compound was prepared starting from 38 through Method C and 
purified by treatment with Et2O, in 89% yield as light-brown solid. 1H NMR (200 MHz, DMSO-
d6):  1.00-1.30 (m, 5H, cyclohexyl CH2), 1.50-1.90 (m, 13H, cyclohexyl CH2 and cycloheptane 
CH2), 2.50-2.60 (m, 2H, cycloheptane CH2), 3.50-3.60 (m, 1H, cyclohexyl CH), 4.00 (s, 3H, 
OCH3), 7.10 (t, J = 7.5 Hz, 1H, aromatic CH), 7.20 (d, J = 8.5 Hz, 1H, NH), 7.55 (t, J = 7.5 Hz, 1H, 
aromatic CH), 7.75 (d, J = 8.1 Hz, 1H, aromatic CH), 8.00 (d, J = 7.7 Hz, 1H, aromatic CH), 11.75 
(s, 1H, NH). 
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6.2.23. General procedure for O-demethylathion reaction for target derivatives 3-16, 22, and 23. 
(Method D) To a solution of the appropriate methoxy derivative (1.0 equiv) in dry CH2Cl2, 1M 
solution of BBr3 in CH2Cl2 (6.0 equiv) was added dropwise maintaining the temperature at 0 °C. 
The reaction mixture was stirred at room temperature for 3-6 h and then quenched with MeOH and 
water. The organic solvent was removed under vacuum affording a residue, which was filtered and 
purified as described below. 
6.2.24. 2-(2-Hydroxybenzamido)-N-(pyridin-2-yl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (3). The title compound was prepared starting from 17 [26] through Method D and 
purified by crystallization by EtOH/H2O, in 48% yield as light-yellow solid. 1H NMR (400 MHz, 
DMSO-d6): δ 1.50-1.65 (m, 4H, cycloheptane CH2), 1.70-1.85 (m, 2H, cycloheptane CH2), 2.65-
2.70 and 2.70-2.80 (m, each 2H, cycloheptane CH2), 6.85-6.95 (m, 2H, aromatic CH), 7.05-7.15 (m, 
1H, pyridine CH), 7.35 (t, J = 7.7 Hz, 1H, aromatic CH), 7.80 (t, J = 7.1 Hz, 1H, pyridine CH), 7.95 
(d, J = 7.7 Hz, 1H, aromatic CH), 8.05 (d, J = 8.1 Hz, 1H, pyridine CH), 8.30 (d, J = 4.6 Hz, 1H, 
pyridine CH), 10.40 (s, 1H, NH), 11.65 (bs, 1H, OH), 11.95 (s, 1H, NH); 13C NMR (101 MHz, 
DMSO-d6): δ 27.5, 28.1, 28.7, 28.8, 32.1, 115.1, 117.1, 117.5, 120.1, 120.2, 121.8, 130.9, 131.4, 
134.2, 135.3, 137.5, 138.4, 148.5, 152.1, 156.7, 162.0, 164.9. HRMS: m/z calcd for C22H21N3O3S 
408.1383 (M+H)+, found 408.1380. 
6.2.25. 2-(3-Hydroxybenzamido)-N-(pyridin-2-yl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (4). The title compound was prepared starting from 39 through Method D and purified 
by flash chromatography eluting with CHCl3:MeOH 98:2, in 13% yield as light-yellow solid. 1H 
NMR (400 MHz, DMSO-d6): δ = 1.50-1.60 (m, 4H, cycloheptane CH2), 1.75-1.85 (m, 2H, 
cycloheptane CH2), 2.65-2.80 (m, 4H, cycloheptane CH2), 6.90-7.00 (m, 1H, aromatic CH), 7.00-
7.10 (m, 1H, aromatic CH), 7.20-7.30 (m, 3H, aromatic CH and pyridine CH), 7.80 (t, J = 7.0 Hz, 
1H, pyridine CH), 8.10 (d, J = 8.3 Hz, 1H, pyridine CH), 8.3 (d, J = 4.1 Hz, 1H, pyridine CH), 9.80 
(s, 1H, OH), 10.25 and 10.90 (s, each 1H, NH); 13C NMR (101 MHz, DMSO-d6): δ 27.5, 28.1, 28.5, 
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28.8, 32.1, 114.7, 115.0, 118.4, 119.5, 120.1, 124.1, 130.1, 132.0, 134.7, 136.2, 136.9, 138.4, 148.4, 
152.3, 157.9, 164.3, 164.4. HRMS: m/z calcd for C22H21N3O3S 408.1383 (M+H)+, found 408.1377. 
6.2.26. 2-(4-Hydroxybenzamido)-N-(pyridin-2-yl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (5). The title compound was prepared starting from 40 through Method D and purified 
by crystallization by EtOH/DMF followed by flash chromatography eluting with CHCl3:MeOH 
98:2, in 32% yield as light-yellow solid. 1H NMR (400 MHz, DMSO-d6):  1.45-1.65 (m, 4H, 
cycloheptane CH2), 1.70-1.85 (m, 2H, cycloheptane CH2), 2.60-2.70 and 2.70-2.80 (m, each 2H, 
cycloheptane CH2), 6.75 (d, J = 8.0 Hz, 2H, aromatic CH), 7.10 (t, J = 7.0 Hz, 1H, pyridine CH), 
7.70 (d, J = 8.0 Hz, 2H, aromatic CH), 7.80 (t, J = 7.2 Hz, 1H, pyridine CH), 8.15 (d, J = 7.7 Hz, 
1H, pyridine CH), 8.25-8.35 (m, 1H, pyridine CH), 10.20 (s, 1H, OH), 10.30 and 10.90 (s, each 1H, 
NH); 13C NMR (101 MHz, DMSO-d6): δ 27.5, 28.1, 28.5, 28.8, 32.1, 115.0, 115.6, 120.1, 123.5, 
123.8, 130.1, 131.7, 136.1, 137.5, 138.4, 148.3, 152.3, 161.5, 163.9, 164.5. HRMS: m/z calcd for 
C22H21N3O3S 408.1383 (M+H)+, found 408.1380. 
6.2.27. 2-(2-Hydroxybenzamido)-N-phenyl-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (6). The title compound was prepared starting from 42 through Method D and purified 
by crystallization by EtOH, in 30% yield as light-yellow solid. 1H NMR (400 MHz, DMSO-d6):  
1.50-1.70 (m, 4H, cycloheptane CH2), 1.75-1.85 (m, 2H, cycloheptane CH2), 2.65-2.80 (m, 4H, 
cycloheptane CH2), 6.80-6.90 (m, 2H, aromatic CH), 7.05 (t, J = 7.3 Hz, 1H, aromatic CH), 7.20-
7.40 (m, 3H, aromatic CH), 7.60 (d, J = 7.7 Hz, 2H, aromatic CH), 7.95 (d, J = 7.1 Hz, 1H, 
aromatic CH), 10.00 (s, 1H, NH), 11.60 (s, 1H, OH), 11.80 (s, 1H, NH); 13C NMR (101 MHz, 
DMSO-d6): δ 27.6, 28.1, 28.8, 28.9, 32.2, 117.1, 117.5, 120.1, 120.5, 122.6, 124.1, 129.1, 131.1, 
131.4, 134.2, 135.2, 136.4, 139.2, 156.7, 161.9, 164.2. HRMS: m/z calcd for C23H22N2O3S 
407.1430 (M+H)+, found 407.1427. 
6.2.28. N-(4-Chlorophenyl)-2-(2-hydroxybenzamido)-5,6,7,8-tetrahydro-4H-
cyclohepta[b]thiophene-3-carboxamide (7). The title compound was prepared starting from 19 
through Method D and purified by crystallization by EtOH, in 55% yield as light-yellow solid. 1H 
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NMR (200 MHz, DMSO-d6):  1.40-1.60 (m, 4H, cycloheptane CH2), 1.60-1.80 (m, 2H, 
cycloheptane CH2), 2.60-2.70 (m, 4H, cycloheptane CH2), 6.80-6.90 (m, 2H, aromatic CH), 7.30-
7.40 (m, 3H, aromatic CH), 7.65 (d, J = 8.8 Hz, 2H, aromatic CH), 7.90 (d, J = 8.0 Hz, 1H, 
aromatic CH), 10.20 (s, 1H, NH), 11.80 and 11.90 (s, each 1H, OH and NH); 13C NMR (101 MHz, 
DMSO-d6): δ27.6, 28.1, 28.8, 32.1, 117.2, 117.5, 120.1, 121.9, 127.7, 129.0, 131.2, 131.3, 134.2, 
135.2, 136.5, 138.2, 156.6, 162.0, 164.2. HRMS: m/z calcd for C23H21ClN2O3S 441.1040 (M+H)+, 
found 441.1034. 
6.2.29. N-(4-Fluorophenyl)-2-(2-hydroxybenzamido)-5,6,7,8-tetrahydro-4H-
cyclohepta[b]thiophene-3-carboxamide (8). The title compound was prepared starting from 43 
through Method D and purified by flash chromatography eluting with cyclohexane:EtOAc 8:2, in 
16% yield as light-yellow solid. 1H NMR (400 MHz, DMSO-d6):  1.50-1.65 (m, 4H, cycloheptane 
CH2), 1.70-1.85 (m, 2H, cycloheptane CH2), 2.65-2.80 (m, 4H, cycloheptane CH2), 6.85-6.95 (m, 
2H, aromatic CH), 7.15 (t, J = 8.8 Hz, 2H, aromatic CH), 7.30 (t, J = 7.7 Hz, 1H, aromatic CH), 
7.60-7.70 (m, 2H, aromatic CH), 7.90 (d, J = 8.0 Hz, 1H, aromatic CH), 10.20 (s, 1H, NH), 11.70 
and 11.90 (s, each 1H, OH and NH); 13C NMR (101 MHz, DMSO-d6):  27.6, 28.1, 28.8, 32.2, 
115.7 (d, JC−F = 22 Hz), 117.1, 117.5, 120.1, 122.2 (d, JC−F = 8 Hz), 122.4, 131.1, 131.4, 134.2, 
135.2, 135.6, 136.4, 157.1(d, JC−F = 87 Hz), 159.9, 161.9, 164.1. HRMS: m/z calcd for 
C23H21FN2O3S 425.1336 (M+H)+, found 425.1335. 
6.2.30. 2-(2-Hydroxybenzamido)-N-(thiazol-2-yl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (9). The title compound was prepared starting from 44 through Method D and purified 
by flash chromatography eluting with CH2Cl2:Acetone 98:2, in 35% yield as light-yellow solid. 1H 
NMR (400 MHz, DMSO-d6):  1.50-1.70 (m, 4H, cycloheptane CH2), 1.75-1.85 (m, 2H, 
cycloheptane CH2), 2.65-2.85 (m, 4H, cycloheptane CH2), 6.80-7.05 (m, 2H, aromatic CH), 7.20-
7.30 (m, 1H, aromatic CH), 7.35 (dt, J = 1.3 and 8.0 Hz, 1H, aromatic CH), 7.50 (d, J = 2.9 Hz, 1H, 
aromatic CH), 7.90 (d, J = 7.0 Hz, 1H, aromatic CH), 11.50 (bs, 1H, NH), 11.75 (bs, 1H, OH), 
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12.25 (s, 1H, NH); 13C NMR (101 MHz, DMSO-d6): δ 26.7, 27.6, 28.1, 28.6, 28.7, 32.2, 117.2, 
117.5, 120.1, 120.4, 131.2, 131.3, 134.3, 135.6, 137.9, 156.8, 162.2. HRMS: m/z calcd for 
C20H19N3O3S2 414.0868 (M+H)+, found 414.0941. 
6.2.31. N-Cyclohexyl-2-(2-hydroxybenzamido)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (14). The title compound was prepared starting from 45 through Method D and 
purified by flash chromatography eluting with cyclohexane:EtOAc 7:3, in 16% yield as light-brown 
solid. 1H NMR (400 MHz, DMSO-d6):  1.20-1.30 and 1.45-1.60 (m, each 5H, cyclohexyl CH2), 
1.60-1.85 (m, 6H, cycloheptane CH2), 2.60-2.70 (m, 4H, cycloheptane CH2), 3.50-3.60 (m, 1H, 
cyclohexyl CH), 6.80-6.90 (m, 2H, aromatic CH and NH), 7.35 (t, J = 7.6 Hz, 1H, aromatic CH), 
7.80 (d, J = 7.6 Hz, 1H, aromatic CH), 7.90 (d, J = 7.6 Hz, 1H, aromatic CH), 11.75 and 11.90 (s, 
1H, OH and NH); 13C NMR (101 MHz, DMSO-d6):  25.1, 25.6, 26.7, 17.6, 28.2, 28.7, 32.2, 32.6, 
48.6, 117.1, 117.7, 120.0, 122.9, 130.7, 131.3, 134.1, 135.1, 135.5, 156.7, 161.7, 164.5. HRMS: m/z 
calcd for C23H28N2O3S 413.1900 (M+H)+, found 413.1899. 
6.2.32. 2-(4-Chlorobenzamido)-N-(2-hydroxyphenyl)-5,6,7,8-tetrahydro-4H-
cyclohepta[b]thiophene-3-carboxamide (22). The title compound was prepared starting from 18 
through Method D and purified by crystallization by EtOH, in 64% yield as light-yellow solid. 1H 
NMR (400 MHz, DMSO-d6):  1.45-1.70 (m, 4H, cycloheptane CH2), 1.75-1.85 (m, 2H, 
cycloheptane CH2), 2.60-2.70 and 2.70-2.80 (m, each 2H, cycloheptane CH2), 6.70-7.00 (m, 3H, 
aromatic CH), 7.60 (d, J = 7.6 Hz, 2H, aromatic CH), 7.80-7.90 (m, 3H, aromatic CH), 9.00 (s, 1H, 
NH), 9.95 and 11.30 (s, each 1H, OH and NH); 13C NMR (101 MHz, DMSO-d6): δ 27.4, 28.1, 28.4, 
28.7, 32.1, 115.8, 119.4, 123.1, 124.0, 125.6, 126.3, 129.3, 129.8, 131.9, 132.8, 135.9, 136.5, 137.5, 
148.6, 163.1, 163.7. HRMS: m/z calcd for C23H21ClN2O3S 441.1040 (M+H)+, found 441.1037. 
6.2.33. N-(3-((2-Hydroxyphenyl)carbamoyl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-2-
yl)picolinamide (23). The title compound was prepared starting from 41 through Method D and 
purified by flash chromatography eluting with CHCl3, in 10% yield as light-yellow solid. 1H NMR 
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(400 MHz, DMSO-d6):  1.55-1.65 (m, 4H, cycloheptane CH2), 1.75-1.85 (m, 2H, cycloheptane 
CH2), 2.70-2.80 and 2.85-3.95 (m, each 2H, cycloheptane CH2), 6.80 (t, J = 7.6 Hz, 1H, aromatic 
CH), 6.90 (d, J = 7.8 Hz, 1H, aromatic CH), 7.00 (t, J = 7.5 Hz, 1H, aromatic CH), 7.60 (m, 1H, 
pyridine CH), 7.90 (d, J = 7.2Hz, 1H, pyridine CH), 8.05 (t, J = 7.5 Hz, 1H, aromatic CH), 8.15 (d, 
J = 7.7 Hz, 1H, pyridine CH), 8.75 (d, J = 4.6 Hz, 1H, pyridine CH), 8.80 (s, 1H, NH), 9.95 (s, 1H, 
OH), 12.15 (s, 1H, NH); 13C NMR (101 MHz, DMSO-d6): δ 27.3, 27.9, 28.6, 28.7, 31.9, 115.8, 
119.5, 121.4, 122.8, 122.9, 125.6, 126.2, 127.9, 132.0, 134.8, 138.3, 138.8, 148.3, 148.5, 149.5, 
161.1, 163.9. HRMS: m/z calcd for C22H21N3O3S 408.1383 (M+H)+, found 408.1381. 
6.2.34. Ethyl 2-(2-methoxybenzamido)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxylate (47). The title compound was prepared starting from ethyl 2-amino-5,6,7,8-tetrahydro-
4H-cyclohepta[b]thiophene-3-carboxylate 46 [30] by Method C (2h) and purified by treatment with 
cyclohexane, in 100% yield as light-yellow solid. 1H NMR (200 MHz, CDCl3): δ 1.35 (t, J = 7.1 
Hz, 3H, CH2CH3), 1.50-1.65 (m, 4H, cycloheptane CH2), 1.75-1.85 (m, 2H, cycloheptane CH2), 
2.65-2.75 and 2.95-3.05 (m, each 2H, cycloheptane CH2), 4.10 (s, 3H, OCH3), 4.35 (q, J = 7.1 Hz, 
2H, CH2CH3), 6.90-7.20 (m, 2H, aromatic CH), 7.40-7.50 (m, 1H, aromatic CH), 8.25 (dd, J = 1.8 
and 7.8 Hz, 1H, aromatic CH), 13.00 (s, 1H, NH). 
6.2.35. 2-(2-Methoxybenzamido)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid 
(48). A suspension of 47 (3.75 mmol, 1.40 g) and LiOH monohydrate (14.99 mmol, 0.63 g) in a 
mixture H2O:THF 1:1 (60 ml) was maintained at 50 °C overnight. After cooling, the reaction 
mixture was acidified (pH = 6) with 2N HCl yielding a precipitate, which was filtered, washed with 
water, and purified by treatment with Et2O to give 47 as light-yellow solid (0.6 g, 46%). 1H-NMR 
(200 MHz, DMSO-d6): δ 1.45-1.60 (m, 4H, cycloheptane CH2), 1.70-1.80 (m, 2H, cycloheptane 
CH2), 2.60-2.70 and 2.95-3.05 (m, each 2H, cycloheptane CH2), 4.00 (s, 3H, OCH3), 7.10 (t, J = 7.7 
Hz, 1H, aromatic CH), 7.20 (d, J = 8.3 Hz, 1H, aromatic CH), 7.55 (dt, J = 1.7 and 8.5 Hz, 1H, 
aromatic CH), 8.00 (dd, J = 1.7 and 7.7 Hz, 1H, aromatic CH), 13.00 (s, 1H, NH). 
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6.2.36. General procedure for C-3 amidation for derivatives 49-54 (Method E).  To a solution of 48 
(1.0 equiv) in dry CH2Cl2 was added the appropriate alkyl amine (3 equiv) followed by BOP (1.5 
equiv) and finally collidine (4.0 equiv). The mixture was stirred at room temperature overnight. The 
mixture was diluted with EtOAc and successively washed with: water (twice), 0.5 M HCl, saturated 
NaHCO3 solution, water, and finally brine. The organic layer was dried over Na2SO4, filtered and 
then evaporated to dryness  providing a residue that was purified as described below.  
6.2.37. 2-(2-Methoxybenzamido)-N-(pyridin-2-ylmethyl)-5,6,7,8-tetrahydro-4H-
cyclohepta[b]thiophene-3-carboxamide (49). The title compound was prepared through Method E 
and purified by flash chromatography eluting with cyclohexane:EtOAc 5:5, in 15% yield as white 
solid. 1H NMR (400 MHz, DMSO-d6): δ 1.50-1.70 (m, 4H, cycloheptane CH2), 1.75-1.85 (m, 2H, 
cycloheptane CH2), 2.60-2.70 and 2.75-2.90 (m, each 2H, cycloheptane CH2), 3.75 (s, 3H, CH3), 
4.60 (d, J = 5.7 Hz, 2H, CH2), 7.00-7.25 (m, 3H, aromatic CH), 7.35 (d, J = 7.8 Hz, 1H, aromatic 
CH), 7.55 (t, J = 7.1 Hz, 1H, aromatic CH), 7.75 (t, J = 7.6 Hz, 1H, aromatic CH), 8.05 (dd, J = 1.5 
and 7.7 Hz, 1H, aromatic CH), 8.35 (d, J = 3.9 Hz, 1H, NH), 8.45-8.55 (m, 1H, aromatic CH), 
12.00 (s, 1H, NH). 
6.2.38. N-Benzyl-2-(2-methoxybenzamido)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (50). The title compound was prepared through Method E and purified by treatment 
with Et2O, in 93% yield as white solid. 1H NMR (200 MHz, DMSO-d6): δ 1.45-1.65 (m, 4H, 
cycloheptane CH2), 1.70-1.85 (m, 2H, cycloheptane CH2), 2.60-2.75 (m, 4H, cycloheptane CH2), 
3.80 (s, 3H, CH3), 4.45 (d, J = 5.7 Hz, 2H, CH2), 7.00-7.30 (m, 7H, aromatic CH and NH), 7.45-
7.60 (m, 1H, aromatic CH), 8.00 (dd, J = 1.7 and 7.8 Hz, 1H, aromatic CH), 8.40 (t, J = 5.7 Hz, 1H, 
aromatic CH), 12.00 (s, 1H, NH). 
6.2.39. N-Isopropyl-2-(2-methoxybenzamido)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (51). The title compound was prepared through Method E and purified by treatment 
with Et2O, in 54% yield as light-yellow solid. 1H NMR (200 MHz, DMSO-d6):  1.10 and 1.15 (s, 
each 3H, CH3), 1.45-1.65 (m, 4H, cycloheptane CH2), 1.70-1.80 (m, 2H, cycloheptane CH2), 2.60-
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2.75 (m, 4H, cycloheptane CH2), 4.00 (s, 3H, OCH3), 4.00-4.10 (m, 1H, CH), 7.10 (t, J = 7.5 Hz, 
1H, aromatic CH), 7.20 (d, J = 8.3 Hz, 1H, aromatic CH), 7.45-7.60 (m, 1H, aromatic CH), 7.75 (d, 
J = 7.9 Hz, 1H, NH), 8.00 (dd, J = 1.7 and 7.8 Hz, 1H, aromatic CH), 11.90 (s, 1H, NH).      
6.2.40. N-(tert-Butyl)-2-(2-methoxybenzamido)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (52). Compound 52 was prepared by Method E and purified by treatment with Et2O, 
in 40% yield as light-yellow solid. 1H NMR (200 MHz, DMSO-d6):  1.30 (s, 9H, CH3), 1.50-1.70 
(m, 4H, cycloheptane CH2), 1.70-1.85 (m, 2H, cycloheptane CH2), 2.60-2.75 (m, 4H, cycloheptane 
CH2), 4.05 (s, 3H, OCH3), 7.10 (t, J = 7.5 Hz, 1H, aromatic CH), 7.20 (d, J = 8.3 Hz, 1H, aromatic 
CH), 7.35 (s, 1H, NH), 7.50-7.60 (m, 1H, aromatic CH), 8.00 (dd, J = 1.6 and 7.7 Hz, 1H, aromatic 
CH), 11.90 (s, 1H, NH).      
6.2.41. 2-Methoxy-N-(3-(4-methylpiperazine-1-carbonyl)-5,6,7,8-tetrahydro-4H-
cyclohepta[b]thiophen-2-yl)benzamide (53). The title compound was prepared through Method E 
purified by flash chromatography eluting with CHCl3:MeOH 97:3, in 26% yield as white solid. 1H 
NMR (400 MHz, CDCl3): δ 1.50-1.70 (m, 4H, cycloheptane CH2), 1.70-1.90 (m, 2H, cycloheptane 
CH2), 2.25 (s, 3H, CH3), 2.30-2.40 (m, 2H, cycloheptane CH2), 2.45-2.65 (m, 4H, piperazine and 
cycloheptane CH2), 2.75-2.85 and 3.25-3.35 (m, each 2H, piperazine CH2), 3.55-3.75 (m, 2H, 
piperazine CH2), 4.00 (s, 3H, OCH3), 6.90 (d, J = 8.3 Hz, 1H, aromatic CH), 7.10 (t, J = 7.4 Hz, 1H, 
aromatic CH), 7.45 (t, J = 7.3 Hz, 1H, aromatic CH), 8.25 (d, J = 7.4 Hz, 1H, aromatic CH). 
6.2.42. 2-Methoxy-N-(3-(4-(pyridin-2-yl)piperazine-1-carbonyl)-5,6,7,8-tetrahydro-4H-
cyclohepta[b]thiophen-2-yl)benzamide (54). The title compound was prepared through Method E 
and purified by flash chromatography eluting with cyclohexane:EtOAc 4:6, in 67% yield as brown 
oil. 1H NMR (400 MHz, CDCl3): δ 1.50-1.70 (m, 4H, cycloheptane CH2), 1.75-1.85 (m, 2H, 
cycloheptane CH2), 2.50-2.70 and 2.80-2.90 (m, each 2H, cycloheptane CH2), 3.25-3.60 (m, 2H, 
piperazine CH2), 3.65-3.80 (m, 2H, piperazine CH2), 3.90-4.05 (m, 4H, piperazine CH2 ), 4.10 (s, 
3H, OCH3), 6.60-6.70 (m, 2H, pyridine CH), 6.90 (d, J = 8.1 Hz, 1H, aromatic CH), 7.10 (t, J = 8.0 
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Hz, 1H, aromatic CH), 7.40-7.50 (m, 2H, aromatic and pyridine CH), 8.10-8.20 (m, 1H, pyridine 
CH), 8.25 (dd, J = 1.8 and 7.8 Hz, 1H, aromatic CH), 11.40 (s, 1H, NH).   
6.2.43. 2-(2-Hydroxybenzamido)-N-(pyridin-2-ylmethyl)-5,6,7,8-tetrahydro-4H-
cyclohepta[b]thiophene-3-carboxamide (10). The title compound was prepared starting from 49 
through Method D and purified by crystallization by EtOH, in 53% yield as light-yellow solid. 1H 
NMR (400 MHz, DMSO-d6,): δ 1.50-1.70 (m, 4H, cycloheptane CH2), 1.75-1.85 (m, 2H, 
cycloheptane CH2), 2.60-2.75 and 2.75-2.90 (m, each 2H, cycloheptane CH2), 4.65 (d, J = 5.3 Hz, 
2H, CH2), 6.85-7.00 (m, 2H, aromatic CH), 7.35 (t, J = 7.4 Hz, 1H, aromatic CH), 7.45-7.55 (m, 
2H, pyridine CH), 7.90 (d, J = 7.7 Hz, 1H, aromatic CH), 8.05 (t, J = 7.0 Hz, 1H, pyridine CH), 
8.55-8.65 (m, 2H, pyridine CH and NH), 11.75 (s, 1H, OH), 12.10 (s, 1H, NH); 13C NMR (101 
MHz, DMSO-d6): δ 27.6, 28.1, 28.5, 28.6, 32.0, 43.4, 117.0, 117.5, 120.2, 121.3, 122.9, 123.9, 
131.3, 131.4, 134.3, 135.1, 136.6, 141.0, 146.3, 156.4, 156.8, 162.0, 165.8. HRMS: m/z calcd for 
C23H23N3O3S 422.1539 (M+H)+, found 422.1539. 
6.2.44. N-Benzyl-2-(2-hydroxybenzamido)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (11). The title compound was prepared starting from 50 through Method D and 
purified by flash chromatography eluting with cyclohexane:EtOAc 8:2, in 9% yield as white solid. 
1H NMR (DMSO-d6, 400 MHz): δ 1.45-1.70 (m, 4H, cycloheptane CH2), 1.75-2.00 (m, 2H, 
cycloheptane CH2), 2.60-2.90 (m, 4H, cycloheptane CH2), 4.50 (d, J = 5.8 Hz, 2H, CH2), 6.80-7.10 
(m, 2H, aromatic CH), 7.20-7.50 (m, 6H, aromatic CH), 8.00 (d, J = 7.8 Hz, 1H, aromatic CH), 
8.50-8.60 (m, 1H, NH), 11.75 and 12.00 (s, each 1H, OH and NH); 13C NMR (101 MHz, DMSO-
d6): δ 27.6, 28.1, 28.6, 28.7, 32.1, 42.8, 117.0, 117.5, 120.2, 122.2, 127.2, 127.6, 128.7, 131.2, 
131.3, 134.2, 135.1, 135.7, 139.6, 156.4, 161.8, 165.4. HRMS: m/z calcd for C24H24N2O3S 
421.1587 (M+H)+, found 421.1586. 
6.2.45. 2-(2-Hydroxybenzamido)-N-isopropyl-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (12). The title compound was prepared starting from 51 through Method D and 
purified by flash chromatography eluting with CHCl3, in 18% yield as white solid. 1H NMR (400 
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MHz, DMSO-d6,):  1.10 (d, J = 6.5 Hz, 6H, CH3), 1.50-1.60 (m, 4H, cycloheptane CH2), 1.70-1.80 
(m, 2H, cycloheptane CH2), 2.60-2.75 (m, 4H, cycloheptane CH2), 3.95-4.05 (m, 1H, CH), 6.90-
7.00 (m, 2H, aromatic CH), 7.30 (dt, J = 1.6 and 7.2 Hz, 1H, aromatic CH), 7.80 (d, J = 7.7 Hz, 1H, 
NH), 7.90 (dd, J = 1.7 and 7.8 Hz, 1H, aromatic CH), 11.75 and 11.0 (s, each 1H, OH and NH); 13C 
NMR (101 MHz, DMSO-d6):  22.6, 27.6, 28.2, 28.6, 28.7, 32.1, 41.4, 117.1, 117.7, 120.0, 123.0, 
130.7, 131.3, 134.0, 135.0, 135.2, 156.7, 161.8, 164.6. HRMS: m/z calcd for C20H24N2O3S 
373.1587 (M+H)+, found 373.1587. 
6.2.46. N-(tert-Butyl)-2-(2-hydroxybenzamido)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (13). The title compound was prepared starting from 52 through Method D and 
purified by flash chromatography eluting with benzene:CHCl3 5:5, in 21% yield as white solid. 1H 
NMR (400 MHz, DMSO-d6):  1.35 (s, 9H, CH3), 1.50-1.60 (m, 4H, cycloheptane CH2), 1.70-1.80 
(m, 2H, cycloheptane CH2), 2.60-2.70 (m, 4H, cycloheptane CH2), 6.90 (t, J = 7.4 Hz, 1H, aromatic 
CH), 7.00 (d, J = 8.0 Hz, 1H, aromatic CH), 7.35 (t, J = 7.1 Hz, 1H, aromatic CH), 7.55 (s, 1H, 
NH), 7.90 (d, J = 7.1 Hz, 1H, aromatic CH), 11.50 and 11.60 (s, each 1H, OH and NH); 13C NMR 
(101 MHz, DMSO-d6):  27.5, 28.2, 28.7, 28.8, 28.9, 32.2, 51.2, 117.2, 117.8, 120.1, 124.4, 130.7, 
131.4, 134.0, 134.4, 135.2, 156.6, 161.7, 165.1. HRMS: m/z calcd for C21H26N2O3S 387.1743 
(M+H)+, found 387.1743. 
6.2.47. 2-Hydroxy-N-(3-(4-methylpiperazine-1-carbonyl)-5,6,7,8-tetrahydro-4H-
cyclohepta[b]thiophen-2-yl)benzamide (15). The title compound was prepared starting from 53 
through Method D and purified by flash chromatography eluting with CHCl3:MeOH 98:2, in 47% 
yield as light-yellow solid. 1H NMR (400 MHz, CDCl3): δ 1.50-1.70 (m, 4H, cycloheptane CH2), 
1.75-1.85 (m, 2H, cycloheptane CH2), 2.25 (s, 3H, CH3), 2.30-2.60 (m, 6H, cycloheptane CH2 and 
piperazine
 
CH2), 2.60-2.70 (m, 2H, piperazine CH2), 3.40-3.80 (m, 4H, cycloheptane CH2 and 
piperazine
 
CH2), 6.85-6.95 (m, 2H, aromatic CH), 7.40 (t, J = 7.6 Hz, 1H, aromatic CH), 7.60 (d, J 
= 7.8 Hz, 1H, aromatic CH), 10.75 (bs, 1H, NH); 13C NMR (101 MHz, CDCl3): δ 27.6, 27.9, 28.8, 
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29.3, 32.5, 45.8, 113.9, 118.4, 119.2, 120.7, 126.5, 133.1, 134.2, 134.5, 135.5, 161.1, 166.0, 167.2. 
HRMS: m/z calcd for C22H27N3O3S 414.1852 (M+H)+, found 414.1849. 
6.2.48. 2-Hydroxy-N-(3-(4-(pyridin-2-yl)piperazine-1-carbonyl)-5,6,7,8-tetrahydro-4H-
cyclohepta[b]thiophen-2-yl)benzamide (16). The title compound was prepared starting 54 through 
Method D and purified by crystallization by EtOH, in 39% yield as white solid. 1H NMR (400 
MHz, CDCl3): δ 1.50-1.70 (m, 6H, cycloheptane CH2), 1.80-1.90 (m, 2H, piperazine CH2), 2.60-
2.70 and 2.75-2.85 (m, each 2H, cycloheptane CH2), 3.30-3.55 (m, 2H, piperazine CH), 3.55-3.75 
(m, 4H, piperazine
 
CH2), 6.60-6.70 (m, 2H, aromatic CH), 6.85 (t, J = 7.7 Hz, 1H, pyridine CH), 
6.95 (d, J = 7.9 Hz, 1H, pyridine CH), 7.40 (dt, J = 1.1 and 8.3 Hz, 1H, aromatic CH), 7.45-7.55 (m, 
2H, pyridine CH), 8.20 (dd, J = 1.8 and 4.9 Hz, 1H, aromatic CH), 10.25 and 11.75 (s, each 1H, NH 
and OH); 13C NMR (101 MHz, CDCl3,): δ 27.7, 28.0, 29.0, 29.3, 32.6, 107.3, 113.5, 114.1, 118.6, 
119.2, 120.6, 126.0, 133.3, 134.1, 134.8, 136.3, 137.7148.0, 158.9, 161.6, 166.1, 167.5. HRMS: m/z 
calcd for C26H28N4O3S 477.1961 (M+H)+, found 477.1957. 
6.3. Biology  
6.3.1. Compounds and peptide. RBV (1-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) was 
purchased from Roche. Each test compound was dissolved in 100% DMSO. The PB1(1–15)–Tat 
peptide was synthesized and purified by the Peptide Facility of CRIBI Biotechnology Center 
(University of Padua, Padua, Italy). This peptide corresponds to the first 15 amino acids of PB1 
protein fused to a short sequence of HIV Tat protein (amino acids 47−59), which allows the 
delivery into the cell [37]. 
6.3.2. Cells and virus. Mardin-Darby canine kidney (MDCK) cells were grown in Dulbecco’s 
modified Eagle’s medium (DMEM, Life Biotechnologies) supplemented with 10% (v/v) fetal 
bovine serum (FBS, Life Technologies) and antibiotics (100 U/mL penicillin and 100 µg/mL 
streptomycin, Life Technologies). The cells were maintained at 37 °C in a humidified atmosphere 
with 5% CO2. Influenza virus strain A/PR/8/34 (H1N1, Cambridge lineage) was kindly provided by 
P. Digard (Roslin Institute, University of Edinburgh, United Kingdom).  
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6.3.3. PA-PB1 interaction enzyme-linked immunosorbent assay (ELISA).  The PA−PB1 interaction 
was detected by a procedure previously described [15]. Briefly, 96-well microtiter plates (Nuova 
Aptca) were coated with 400 ng of 6His-PA(239−716) for 3 h at 37 °C and then blocked with 2% BSA 
(Sigma) in PBS for 1 h at 37 °C. The 6His-PA(239−716) protein was expressed in E. coli strain 
BL21(DE3)pLysS and purified as already described [15]. After washing, 200 ng of GST-PB1(1−25), 
or of GST alone as a control, in the absence or the presence of test compounds at various 
concentrations, were added and incubated O/N at room temperature. Escherichia coli-expressed, 
purified GST and GST-PB1(1−25) proteins were obtained as previously described [15, 38]. After 
washing, the interaction between 6His-PA(239−716) and GST-PB1(1−25) was detected with a 
horseradish peroxidase-coupled anti-GST monoclonal antibody (GenScript) diluted 1:4,000 in PBS 
supplemented with 2% FBS. Following washes, the  substrate 3,3′,5,5′tetramethylbenzidine (TMB, 
KPL) was added and absorbance was measured at 450 nm by an ELISA plate reader (Tecan 
Sunrise™). Values obtained from the samples treated with only DMSO were used to set as 100% of 
PA−PB1 interaction.  
6.3.4. Cytotoxicity assay. Cytotoxicity of compounds was tested in MDCK cells by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) method, as previously reported [15, 
39]. Briefly, MDCK cells (seeded at density of 2 x 104 per well) were grown in 96-well plates for 
24 h and then treated with serial dilutions of test compounds, or DMSO as a control, in DMEM 
supplemented with 10% FBS. After incubation at 37 °C for 48 h, 5 mg/mL of MTT (Sigma) in PBS 
was added into each well and incubated at 37 °C for further 4 h. Successively, a solubilization 
solution was added to lyse the cells and incubated O/N at 37 °C. Finally, optical density was read at 
the wavelength of 620 nm on a microtiter plate reader.  
6.3.5. Plaque reduction assay (PRA).  The antiviral activity of test compounds against influenza A 
virus was tested by PRA as previously described [15]. MDCK cells were seeded at 5 x 105 
cells/well into 12-well plates, and incubated at 37°C for 24 h. The following day, the culture 
medium was removed and the monolayers were first washed with serum-free DMEM and then 
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infected with the flu A/PR/8/34 strain at 40 PFU/well in DMEM supplemented with 1 μg/mL of 
TPCK-treated trypsin (Worthington Biochemical Corporation) and 0.14% BSA and incubated for 1 
h at 37 °C. The influenza virus infection was performed in the presence of different concentrations 
of test compounds or solvent (DMSO) as a control. After virus adsorption, DMEM containing 1 
μg/mL of TPCK-treated trypsin, 0.14% BSA, 1.2% Avicel, and DMSO or test compounds was 
added to the cells. At 48 h post-infection, cells were fixed with 4% formaldehyde and stained with 
0.1% toluidine blue. Viral plaques were counted, and the mean plaque number in the DMSO-treated 
control was set at 100%. 
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Figure legends 
Fig. 1. Structures of cHTC derivatives 1 and 2.  
Fig. 2. FLAP binding poses for compounds 1 (A), 3 (B), 4 (C), and 5 (D). Some of the PA key 
residues located in the cavity are highlighted in stick-mode. 
 
Scheme Footnotes 
Scheme 1. Synthesis of compounds 3-9, 14, 18, 19, 22, and 23. Reagents and conditions: (i) 
amines, toluene, reflux; (ii) cycloheptanone, ammonium acetate, glacial acetic acid, benzene, reflux; 
(iii) sulfur, N,N-diethylamine, EtOH, 40−50 °C; (iv) acyl chlorides, pyridine, rt; (v) BBr3, dry 
CH2Cl2, rt.  
Scheme 2. Synthesis of compounds 10-13, 15, and 16. Reagents and conditions: (i) 2-
methoxybenzoyl chloride, pyridine, rt; (ii) LiOH, H2O/THF, 50 °C; (iii) amines, BOP, collidine, dry 
CH2Cl2, rt; (iv) BBr3, dry CH2Cl2, rt. 
 
Abbreviations: 
Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate, (BOP); 
cycloheptathiophene-3-carboxamide, (cHTC); fingerprints for ligands and proteins, (FLAP); 
Influenza virus (flu), mardin-darby canine kidney, (MDCK); plaque reduction assays, (PRA); 
polymerase acidic protein, (PA); polymerase basic protein 1, (PB1); polymerase basic protein 2, 
(PB2); protein-protein interaction, (PPI); ribavirin, (RBV); RNA-dependent RNA polymerase, 
(RdRp); structure-activity relationship (SAR). 
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Highlights 
     Cycloheptathiophene-3-carboxamide scaffold is a suitable to achieve PA-PB1 interaction 
inhibition; 
      Compounds 9 and 21 showed potent anti-influenza activity; 
      The o-hydroxyphenyl moiety induces a significant change of the binding mode of the 
compounds 
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